R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized Nordic Lymphoma Group phase III trial - NLG-LBC7 (POLAR BEAR)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502887-19-00

Acronym

NLG-LBC7

Enrollment

259

Registered

2023-07-26

Start date

2020-08-18

Completion date

Unknown

Last updated

2025-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B-Cell Lymphoma

Brief summary

Progression-free survival

Detailed description

Response duration, Complete remission rate, Overall response rate, Health-related quality of life, Overall survival, Lymphoma-specific survival, Safety

Interventions

DRUGPREDNISONE

DRUGPolivy 140 mg powder for concentrate for solution for infusion

DRUGRITUXIMAB

DRUGCYCLOPHOSPHAMIDE

DRUGVINCRISTINE SULFATE

DRUGDOXORUBICIN HYDROCHLORIDE

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
Response duration, Complete remission rate, Overall response rate, Health-related quality of life, Overall survival, Lymphoma-specific survival, Safety	—

Countries

Denmark, Estonia, Finland, Italy, Norway, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026